InvestorsHub Logo
Followers 466
Posts 26944
Boards Moderated 2
Alias Born 09/11/2006

Re: surf1944 post# 43

Thursday, 06/27/2013 2:13:31 PM

Thursday, June 27, 2013 2:13:31 PM

Post# of 138
8:04AM Supernus Pharma announces Paragraph IV ANDA filing for Oxtellar XR (SUPN) 6.27 : SUPN announced that on June 26, 2013 the Company received a Paragraph IV Notice Letter from Watson Laboratories advising Supernus of the filing by Watson of an Abbreviated New Drug Application seeking approval for oxcarbazepine extended-release tablets. Supernus is currently reviewing the details of this Notice Letter and intends to vigorously enforce its intellectual property rights relating to Oxtellar XR. The product is currently protected by two issued patents that are listed in the FDA's Orange Book.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SUPN News